Aggressive lymphomas: Prospective studies

 
Gerhard Held, Lorenz Thurner, Viola Pöschel, et al. 
 
The authors of the abstract conclude: 
To our knowledge, this is the largest series of PMBCLs so far, which have been treated in a prospective, randomized trial in the Rituximab era. The results reveal no differences in outcome between R-CHOP-14 vs R-CHOP-21. Pts assigned to RT had a superior EFS mostly due to a higher PR rate in the no RT arm triggering RT, with no differences in PFS and OS. The results suggest a benefit of RT only for pts, who are responding to R-CHOP with PR according to Internat Standardized Response Criteria (Cheson 1999). Testing RT in PET-positive residual tumors in a randomized trial can solve the question, while RT in PET-negative pts is studied in the ongoing randomized IELSG 37 trial. Our results indicate a very favorable 3-year OS of 96% in PMBCL pts treated with R-CHOP. Supported by Deutsche Krebshilfe, Amgen and Roche
————————————————————————————————————————————————————————
 
 
Emanuele Zucca, Luciano Cascione, Sämi Schär, et al.
 
The authors of the abstract conclude: 
Interim PET can identify poor-risk patients. In keeping with another recent report (Schmitz et al. Eur J Cancer, 2020), we showed that a prognostic model based on MTV at diagnosis and ΔSUVmax may allow early recognition of refractory patients who might benefit from alternative treatments. We also showed that a residual lesion uptake >2 times above the liver SUVmax after 2 R-CHOP-14 cycles is the best prognostic cut-off point, suggesting that a purely visual definition of DS should be replaced by a semi-quantitative evaluation. Moreover, this study showed that absolute values of MTV and TLG maintained at the interim PET the prognostic validity they had in baseline scans and that SUVmax at interim is a powerful outcome predictor. These findings indicate that, interim PET/CT staging may be very useful also in patients who for any reasons did not had baseline PET scans, even though ΔSUVmax cannot be obtained and interpretation of DS is hindered by the lack of prior scans.
————————————————————————————————————————————————————————
 
 
Elizabeth Phillips, Amy A Kirkwood, Sharon Barrans, et al.
 
The authors of the abstract conclude: 
To our knowledge, this is the first randomised trial of frontline DLBCL treatment for anthracycline-unfit pts. We did not demonstrate superiority for IO over G in this challenging pt group with high NRM. However, IO-R-CVP is an effective and deliverable regimen for DLBCL in high-risk, co-morbid pts, particularly those with high IPI, in whom fewer cycles of G-R-CVP were delivered.
————————————————————————————————————————————————————————
 
 
Carmelo Carlo-Stella, Pier Luigi Zinzani, Brad Kahl, et al.
 
The authors of the abstract conclude: 
Lonca had substantial single-agent antitumour activity in pts with R/R DLBCL who failed established therapies. The ORR exceeded the primary endpoint target for the trial, reinforcing the potential for Lonca to fill a critical unmet need and become a key part of the treatment paradigm for heavily pretreated pts with DLBCL. The toxicity profile was manageable and no new safety concerns were identified. Updated results, including duration-of-response and subsequent treatments, will be presented at the meeting.
————————————————————————————————————————————————————————
 
 
Charles Herbaux, Olivier Casasnovas, Pierre Feugier, et al.
 
The authors of the abstract conclude: 
The ATE, OBI and VEN combination appears to be well tolerated. The OMRR rate at EOI is comparable with currently available treatment options in this population, with durable responses. The OMRR seems better in patients with a low tumor burden.
 
————————————————————————————————————————————————————————
MORE STATEMENTS ABOUT LYMPHOMA Visit vjhemonc.com